Amedeo Smart

Free Medical Literature Service


 

Amedeo

Alzheimer's Disease

  Free Subscription

Articles published in
N Engl J Med
    October 2024
  1. LOPERA F, Arboleda-Velasquez JF
    APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease. Reply.
    N Engl J Med. 2024;391:1661.
    >> Share

  2. COCHRAN JN, Greicius MD, Goate AM
    APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease.
    N Engl J Med. 2024;391:1660-1661.
    >> Share

    June 2024
  3. CHIN NA, Erickson CM
    Alzheimer's Disease, Biomarkers, and mAbs - What Does Primary Care Need?
    N Engl J Med. 2024;390:2229-2231.
    >> Share

  4. STEFANSSON H, Walters GB, Sveinbjornsson G, Tragante V, et al
    Homozygosity for R47H in TREM2 and the Risk of Alzheimer's Disease.
    N Engl J Med. 2024;390:2217-2219.
    >> Share

  5. HARDY J
    Protection against Alzheimer's Disease with APOE Christchurch Variant - How?
    N Engl J Med. 2024;390:2212-2213.
    >> Share

  6. QUIROZ YT, Aguillon D, Aguirre-Acevedo DC, Vasquez D, et al
    APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease.
    N Engl J Med. 2024;390:2156-2164.
    >> Share

    March 2024
  7. CHIN NA, Dinsmore D, Gonzales T, Groves B, et al
    Alzheimer's Disease - Managing Stages of Dementia.
    N Engl J Med. 2024;390:e29.
    >> Share

  8. CHIN NA, Dinsmore D, Gonzales T, Groves B, et al
    Alzheimer's Disease - Anti-Amyloid Medications, Early Detection, and Screening.
    N Engl J Med. 2024;390:e22.
    >> Share

    February 2024
  9. BATEMAN RJ, Smith J, Doody RS
    Gantenerumab in Early Alzheimer's Disease. Reply.
    N Engl J Med. 2024;390:867.
    >> Share

  10. WANG Z, Zhao B, Jia J
    Gantenerumab in Early Alzheimer's Disease.
    N Engl J Med. 2024;390:866.
    >> Share

  11. MAYEUX R
    Alzheimer's Disease Biomarkers - Timing Is Everything.
    N Engl J Med. 2024;390:761-763.
    >> Share

  12. JIA J, Ning Y, Chen M, Wang S, et al
    Biomarker Changes during 20 Years Preceding Alzheimer's Disease.
    N Engl J Med. 2024;390:712-722.
    >> Share

    January 2024
  13. REZAI AR, D'Haese PF, Finomore V, Carpenter J, et al
    Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer's Disease.
    N Engl J Med. 2024;390:55-62.
    >> Share

    November 2023

  14. Alzheimer's Update, Part 2: ITT Episode 21.
    N Engl J Med. 2023;389:e43.
    >> Share

  15. SCHNEIDER LS
    What the Gantenerumab Trials Teach Us about Alzheimer's Treatment.
    N Engl J Med. 2023;389:1918-1920.
    >> Share

  16. BATEMAN RJ, Smith J, Donohue MC, Delmar P, et al
    Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
    N Engl J Med. 2023;389:1862-1876.
    >> Share


  17. Alzheimer's Update, Part 1: ITT Episode 20.
    N Engl J Med. 2023;389:e33.
    >> Share

    July 2023
  18. SPERLING RA, Donohue MC, Raman R, Rafii MS, et al
    Trial of Solanezumab in Preclinical Alzheimer's Disease.
    N Engl J Med. 2023 Jul 17. doi: 10.1056/NEJMoa2305032.
    >> Share

    April 2023
  19. VAN DYCK CH, Sabbagh M, Cohen S
    Lecanemab in Early Alzheimer's Disease. Reply.
    N Engl J Med. 2023;388:1631-1632.
    >> Share

  20. BRENMAN JE
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1631.
    >> Share

  21. POMARA N, Imbimbo BP
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1630-1631.
    >> Share

  22. VALENZUELA MJ, Pascual-Leone A
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1630.
    >> Share

  23. ZENG BS, Tseng PT, Liang CS
    Lecanemab in Early Alzheimer's Disease.
    N Engl J Med. 2023;388:1630.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016